Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders
Status:
Recruiting
Trial end date:
2021-11-21
Target enrollment:
Participant gender:
Summary
This study aims to assess the role of ribavirin as an adjuvant to
sofosbuvir/velpatasvir/voxilaprevir combination in retreatment of chronic hepatitis C with
previous treatment failure.
Phase:
Phase 4
Details
Lead Sponsor:
Helwan University
Treatments:
Ribavirin Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir